-+ 0.00%
-+ 0.00%
-+ 0.00%

Cantor Fitzgerald Maintains Overweight on Exagen, Lowers Price Target to $7

Benzinga·05/15/2025 15:36:22
Listen to the news
Cantor Fitzgerald analyst Ross Osborn maintains Exagen (NASDAQ:XGN) with a Overweight and lowers the price target from $8 to $7.